反应详情

Following the procedure for 1-((1H-imidazol-2-yl)methyl)-6-(4-(1-aminocyclobutyl)phenyl)-7-phenyl-1H-pyrido[2,3-b][1,4]oxazin-2(3H)-one, tert-butyl(1-(4-(1-oxo-8-phenyl-2-(2,2,2-trifluoroethyl)-2,4-dihydro-1H-pyrido[2,3-b][1,2,4]triazolo[4,3-d][1,4]oxazin-7-yl)phenyl)cyclobutyl)carbamate (45 mg, 0.08 mmol) was reacted to afford the title compound (34 mg, 61%). LCMS (Method D): RT=0.923 min, M-NH2=477. 1H NMR (500 MHz, MeOD): 8.43 (1H, s), 7.34-7.28 (4H, m), 7.21-7.20 (3H, m), 7.13-7.12 (2H, m), 5.34 (2H, s), 4.49 (2H, q), 2.70-2.62 (2H, m), 2.49-2.43 (2H, m), 2.15-2.08 (1H, m), 1.91-1.77 (1H, m).

1. customwas reacted